TWIST BIOSCIENCE CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.54 USD | +1.48% |
|
+12.84% | -14.43% |
Valuation
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 775.4 | 3,393 | 5,273 | 1,986 | 1,163 | 1,824 | - | - |
| Enterprise Value (EV) 1 | 645 | 3,108 | 4,808 | 1,608 | 876.4 | 1,651 | 1,685 | 1,707 |
| P/E ratio | -6.09 x | -21.3 x | -34 x | -8.72 x | -5.63 x | -10.3 x | -12 x | -17.1 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 14.3 x | 37.7 x | 39.8 x | 9.76 x | 4.74 x | 6.22 x | 5.15 x | 4.23 x |
| EV / Revenue | 11.9 x | 34.5 x | 36.3 x | 7.9 x | 3.58 x | 5.63 x | 4.76 x | 3.96 x |
| EV / EBITDA | -6.28 x | -28 x | -33.5 x | -7.37 x | -4.67 x | -11 x | -12.8 x | -138 x |
| EV / FCF | -6.28 x | -20.4 x | -34.5 x | -7.11 x | -5.15 x | -15.7 x | -18 x | -23.1 x |
| FCF Yield | -15.9% | -4.89% | -2.9% | -14.1% | -19.4% | -6.38% | -5.54% | -4.33% |
| Price to Book | 4.3 x | 10.2 x | 9.12 x | 2.52 x | 1.87 x | 3.59 x | 4.16 x | 5.19 x |
| Nbr of stocks (in thousands) | 32,472 | 44,663 | 49,292 | 56,364 | 57,396 | 57,818 | - | - |
| Reference price 2 | 23.88 | 75.97 | 107.0 | 35.24 | 20.26 | 31.54 | 31.54 | 31.54 |
| Announcement Date | 11/12/19 | 23/11/20 | 22/11/21 | 18/11/22 | 17/11/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 54.38 | 90.1 | 132.3 | 203.6 | 245.1 | 293.1 | 354 | 430.9 |
| EBITDA 1 | -102.7 | -110.9 | -143.5 | -218.3 | -187.8 | -150.6 | -131.2 | -12.35 |
| EBIT 1 | -108.8 | -117.6 | -153.3 | -234.8 | -217.2 | -188.3 | -162.5 | -116.2 |
| Operating Margin | -200.15% | -130.5% | -115.81% | -115.33% | -88.6% | -64.23% | -45.91% | -26.98% |
| Earnings before Tax (EBT) 1 | -107.4 | -139.5 | -154 | -228.3 | -203.5 | -178.6 | -158.5 | -108.4 |
| Net income 1 | -107.7 | -139.9 | -152.1 | -217.9 | -204.6 | -180.3 | -159 | -109.3 |
| Net margin | -197.98% | -155.31% | -114.94% | -107.02% | -83.48% | -61.52% | -44.91% | -25.37% |
| EPS 2 | -3.920 | -3.570 | -3.150 | -4.040 | -3.600 | -3.075 | -2.636 | -1.845 |
| Free Cash Flow 1 | -102.7 | -152.1 | -139.3 | -226.2 | -170.3 | -105.3 | -93.41 | -73.95 |
| FCF margin | -188.83% | -168.84% | -105.27% | -111.14% | -69.46% | -35.94% | -26.39% | -17.16% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 11/12/19 | 23/11/20 | 22/11/21 | 18/11/22 | 17/11/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: September | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 37.95 | 42.02 | 48.13 | 56.11 | 57.31 | 54.24 | 60.18 | 63.74 | 66.95 | 71.5 | 70.76 | 73.92 | 77.34 | 83.6 | 83.76 |
| EBITDA 1 | -39.8 | -55.62 | -56.83 | -56.72 | - | -43.47 | - | -52.29 | -41.61 | -38.81 | -39.4 | -38.2 | -36.65 | - | - |
| EBIT 1 | -42.23 | -58.77 | -60.8 | -61.16 | -56.87 | -48.76 | -62.83 | -60.78 | -50.11 | -46.98 | -49.57 | -47.06 | -43.66 | -38.08 | -43.26 |
| Operating Margin | -111.28% | -139.86% | -126.34% | -109% | -99.24% | -89.9% | -104.41% | -95.36% | -74.85% | -65.7% | -70.06% | -63.67% | -56.45% | -45.55% | -51.65% |
| Earnings before Tax (EBT) 1 | -40.9 | -55.97 | -60.82 | -60.67 | -50.82 | -41.75 | -58.48 | -56.77 | -46.46 | -42.89 | -48.37 | -47.15 | -44.99 | -43.29 | -42.31 |
| Net income 1 | -41.24 | -45.56 | -60.67 | -60.52 | -51.12 | -41.82 | -59.16 | -57.4 | -46.24 | -43.01 | -48.71 | -47.28 | -45 | -43.42 | -43.13 |
| Net margin | -108.67% | -108.44% | -126.06% | -107.85% | -89.2% | -77.1% | -98.3% | -90.05% | -69.08% | -60.15% | -68.84% | -63.97% | -58.19% | -51.94% | -51.5% |
| EPS 2 | -0.8400 | -0.9100 | -1.130 | -1.080 | -0.9100 | -0.7400 | -1.040 | -1.010 | -0.8100 | -0.7500 | -0.8231 | -0.7812 | -0.7302 | -0.6150 | -0.7400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 22/11/21 | 04/02/22 | 05/05/22 | 05/08/22 | 18/11/22 | 03/02/23 | 05/05/23 | 04/08/23 | 17/11/23 | 02/02/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 130 | 285 | 464 | 379 | 286 | 173 | 139 | 117 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -103 | -152 | -139 | -226 | -170 | -105 | -93.4 | -73.9 |
| ROE (net income / shareholders' equity) | -89.1% | -57.3% | -33.2% | -31.8% | -29% | -33.8% | -37.6% | -40.4% |
| ROA (Net income/ Total Assets) | -51.4% | -47.8% | -27.6% | -26.2% | -23.5% | -26.9% | -29.2% | -27.3% |
| Assets 1 | 209.3 | 292.9 | 550.5 | 831.7 | 868.9 | 671.3 | 544.2 | 400.5 |
| Book Value Per Share 2 | 5.550 | 7.460 | 11.70 | 14.00 | 10.80 | 8.780 | 7.590 | 6.080 |
| Cash Flow per Share 2 | -3.200 | -3.630 | -2.330 | -2.310 | -2.510 | -1.480 | -1.280 | -0.8600 |
| Capex 1 | 14.8 | 9.87 | 27.1 | 102 | 27.8 | 15 | 24 | 22.9 |
| Capex / Sales | 27.13% | 10.95% | 20.45% | 50.04% | 11.33% | 5.12% | 6.78% | 5.32% |
| Announcement Date | 11/12/19 | 23/11/20 | 22/11/21 | 18/11/22 | 17/11/23 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
31.54
USD
Average target price
40.25
USD
Spread / Average Target
+27.62%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.43% | 1.82B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.35B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- TWST Stock
- Financials Twist Bioscience Corporation
